NCT06616194: An ongoing trial by Pfizer
This trial is ongoing. It must report results 1 year, 9 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06616194 |
|---|---|
| Title | AN INTERVENTIONAL, EFFICACY, AND SAFETY, PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN OPEN-LABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 15, 2024 |
| Completion date | Oct. 8, 2026 |
| Required reporting date | Oct. 8, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |